SUBSCRIBE
SUBSCRIBE
News   Drug Development

Daiichi Suntory Pharma Co., Ltd. to Move Clot Prevention Drug to Phase 3

October 31, 2008 | 
1 min read
TOKYO, Oct 31 (Reuters) - Japanese drugmaker Daiichi Sankyo Co Ltd said on Friday it would advance its DU-176b clot prevention drug to Phase III trials, the final stage before marketing approval, in November.
Clinical research Phase III Asia
MORE ON THIS TOPIC
Creative collage illustration of financial business. Two businessmen shaking hands for partners agreement. Conceptual illustration of success deal, corporate ethic, connection.
Collaboration
Kite Makes $1.5B+ Cell Therapy Pact With Pregene as Others Pull Back
October 17, 2025
 · 
2 min read
 · 
Tristan Manalac
REGULATORY
Webinar: Shifting Risk | Biopharma in an Age of Deregulation
October 16, 2025
 · 
1 min read
 · 
BioSpace Insights
IN PARTNERSHIP WITH PII
Work Smart, Build Trust: Connecting Technology, Patient Compliance and Data Processing
October 16, 2025
 · 
1 min read
 · 
BioSpace Insights
Check mate. hand of businessman moving chess figure Trendy 3d collage in magazine style. Contemporary art. Modern design
GLP-1
Lilly’s Oral GLP-1 Bests Another Big Pharma Bestseller in Phase III Diabetes Trial
October 15, 2025
 · 
2 min read
 · 
Annalee Armstrong